Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(3.19)
# 1,255
Out of 4,496 analysts
39
Total ratings
43.59%
Success rate
4.14%
Average return
Main Sectors:
Top Industries:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Overweight | n/a | $75.97 | - | 6 | Jun 20, 2024 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $2.15 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $8.80 | - | 5 | Jun 20, 2024 | |
| BLTE Belite Bio | Reiterates: Overweight | n/a | $50.33 | - | 3 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $0.69 | - | 4 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $1.59 | - | 3 | May 15, 2024 | |
| PSTX Poseida Therapeutics | Reiterates: Overweight | $14 | $3.06 | +357.52% | 2 | Oct 10, 2023 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $1.66 | +20.48% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $2.58 | +442.64% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $5.65 | +484.07% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $1.79 | +152.10% | 2 | May 17, 2023 | |
| AYTU Aytu BioPharma | Maintains: Overweight | $220 → $100 | $2.79 | +3,484.23% | 2 | May 17, 2022 |
Insmed
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $75.97
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.15
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.80
Upside: -
Belite Bio
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $50.33
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.69
Upside: -
Precigen
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.59
Upside: -
Poseida Therapeutics
Oct 10, 2023
Reiterates: Overweight
Price Target: $14
Current: $3.06
Upside: +357.52%
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.66
Upside: +20.48%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $2.58
Upside: +442.64%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $5.65
Upside: +484.07%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.79
Upside: +152.10%
Aytu BioPharma
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $2.79
Upside: +3,484.23%